NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
31/12/2024
Voltar para busca
Dado oficial do USPTO
HIKMA. 503B
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
38
Atualização mais recente
31/12/2024
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 16, 44
Data de depósito
25/06/2021
Data de registro
31/12/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
31/12/2024
Última transação
31/12/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
2021-06-00
Primeiro uso no comércio
2021-12-00
Código do desenho
5
Tipo de titular
03
Localização do titular
Berkeley Heights, NJ
Examinador
FAIRBANKS, RONALD
Unidade examinadora
N10
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the wording "hikma." in coral red, above the numbers/letter "503B" in navy blue.
Titulares e representantes
Titulares
Hikma Injectables USA Inc.
Representantes
Michelle E. Tochtrop Chrisman Gallo Tochtrop LLC
Classificação técnica
Classes Nice
Classe 5Classe 16Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and medicinal preparations and substancessystemic anti-infectivespharmaceutical and medicinal substances for the preventioncuringtreatment of viralmetabolicalimentaryendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalparasiticpsychiatricimmune system related diseases and disorders; pharmaceutical and medicinal substances for the preventioncuringtreatment of allergiesinflammationpaininfectious diseasesblood diseases and disordersnervous system diseases and disordersmalignant neoplastic diseases and disordersimmunomodulating agent diseases and disorders; chemical preparations for pharmaceutical or medical purposesfor viralmetabolicalimentaryendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalparasiticpsychiatricimmune system related diseases and disordersallergiesinflammationpaininfectious diseasesblood diseases and disordersnervous system diseases and disordersmalignant neoplastic diseases and disordersimmunomodulating agent diseases and disorders
Classe 16
Papercardboard; articles of paper or cardboardbagsenvelopespaper packaging materialspacking paperpacking cardboardnotebooksnotepadsfoldersbookmarkerscalendarsboxescoastersstationery paperpostersposter boardpaper stationery; printed matterprinted booksbookletsjournalsmagazinesnewspapersperiodicalspamphletsbrochuresmanualsleafletsinformational flyersinformational sheetsnewslettersinstructional worksheets all in the fields of medicinemedical technologypharmaceuticalshealthcare; printed instructional and teaching materialsprinted booksbookletsjournalsmagazinesnewspapersperiodicalspamphletsbrochuresmanualsleafletsinformational flyersinformational postersinformational sheetsnewslettersinstructional worksheets all in the fields of medicinemedical technologypharmaceuticalshealthcare; stationery; adhesive materialsadhesives for stationery or household purposesadhesive stickersadhesive notepads
Classe 44
Pharmaceutical compounding services; medical testing and analysis for diagnostic or treatment purposes; genetic testing for medical purposes; advisory services relating to healthcare being medical diagnostic and treatment advisory services relating to health
Publicações
Histórico de despachos e eventos da marca no USPTO.
38 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
31/12/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
26/11/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/11/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/11/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
27/10/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
27/10/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
27/10/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
27/10/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
27/10/2024
SNEA
SU-EXAMINER'S AMENDMENT WRITTEN
27/10/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
03/07/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
03/07/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/04/2024
GNRT
NON-FINAL ACTION E-MAILED
08/04/2024
CNRT
SU - NON-FINAL ACTION - WRITTEN
08/04/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
09/01/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
09/01/2024
IUAF
USE AMENDMENT FILED
20/12/2023
EISU
TEAS STATEMENT OF USE RECEIVED
20/12/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
28/06/2023
EX1G
SOU EXTENSION 1 GRANTED
26/06/2023
EXT1
SOU EXTENSION 1 FILED
26/06/2023
EEXT
SOU TEAS EXTENSION RECEIVED
26/06/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
27/12/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/11/2022
PUBO
PUBLISHED FOR OPPOSITION
01/11/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/10/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
26/09/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/09/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/09/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/09/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
24/03/2022
GNRT
NON-FINAL ACTION E-MAILED
24/03/2022
CNRT
NON-FINAL ACTION WRITTEN
24/03/2022
DOCK
ASSIGNED TO EXAMINER
16/03/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/09/2021
NWAP
NEW APPLICATION ENTERED
29/06/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace HIKMA. 503B ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.